Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer

a technology of prolactin receptor and chemotherapeutic drugs, which is applied in the direction of drug compositions, peptides/proteins, peptides, etc., can solve the problems of prolactin increasing the risk of systemic malignancies such as leukemia, poor overall patient prognosis, and poor prognosis of cancer types

Inactive Publication Date: 2013-09-05
ONCOLIX
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In comparison to other known breast cancer subtypes, the triple-negative subtype is more aggressive, less responsive to standard treatment and is associated with poorer overall patient prognosis.
This type of cancer usually has a poor prognosis.
Recent studies also suggest that prolactin increases the risk for systemic malignancies such as leukemias.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer
  • Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer
  • Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Human Prolactin Antagonist G129R

[0065]Human PRL was successfully cloned using reverse transcription (RT) followed by polymerase chain reaction (PCR). Briefly, human pituitary polyA RNA (CloneTech, Inc. Palo Alto, Calif.) was used as template. A HPRL antisense primer was designed starting 2 bases from the stop codon (TAA) of hPRL cDNA (5′-GCTTAGCAGTTGTTGTTGTG-3′; SEQ ID NO: 1) and a sense primer was designed from ATG (5′-ATGAACATCAAAGGAT-3′; SEQ ID NO: 2). RT / PCR was carried out using a kit from Perkin-Elmer Cetus, Inc. (Norwalk, Conn.). The nucleotide sequence of the resulting hPRL was determined by the dideoxy chain-termination method using modified T7 DNA polymerase (Sequenase, United States Biochemical), and was found to be identical to that reported in GenBank except for a one base difference which results in a silent mutation at codon 21 (CTG→CTC). A schematic representation of the cloning process, including preparation of the pUCIG-Met expression vector, is summ...

example 2

Treatment of Triple-Negative Breast Cancer Cells with Prolactin Receptor Antagonist G129R Results in the Decreased ALDH1 Activity in the Cells

[0069]Human triple-negative breast cancer cells MDA-MB-231 and control breast cancer cells T-47D were plated in 6 well plates at 1×105 cells / ml, and allowed to adhere for 24 hours in growth media followed by 2 hours of serum free media depletion. The cells were then cultured either without (control) or with prolactin (100 ng / ml) or G129R (10 ug / ml) for three days. The cells were then collected and the ALDH-1 activity (this enzyme is a marker for cancer stem cells. See Ginestier et al., Cell Stem Cell 2007 1(5): 555-567) was measured by ALDEFLUORR fluorescent assay (StemCell Technologies). As shown in FIG. 1, treatment with prolactin antagonist G129R significantly reduced the ALDH1 activity in triple-negative breast cancer cells.

example 3

Treatment with Prolactin Receptor Antagonist Reduces the ALDH1 Activity in Tumor Cells

[0070]MMTV / neu transgenic mice carry an activated c-neu oncogene driven by a mouse mammary tumor virus (MMTV) promoter and develop mammary HER2+ adenocarcinomas (Muller et al. 1988. Cell. 54(1):105-15). MMTV / neu transgenic mice bearing mammary tumors were treated with PBS (n=4) or G129R for 5 (n=2) or 10 (n=3) days (10 mg / kg, i.p.). The tumors were isolated at the end of treatment, digested to a single cell suspension, and ALDH1 activity levels were compared. As can be seen from FIG. 2, the ALDH1 activity was significantly reduced in cancer cells isolated from animals treated with G129R. Practically no ALDH1 activity was detected in cancer cells that were treated with G129R for ten days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
magnetic resonance imagingaaaaaaaaaa
nuclear magnetic resonance imagingaaaaaaaaaa
fluorescentaaaaaaaaaa
Login to view more

Abstract

The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. patent application Ser. No. 12 / 948,329 filed Nov. 17, 2010, the contents of which is incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that are useful in eliminating HER2− breast cancer cells, triple-negative breast cancer cells that do not express estrogen receptor, progesterone receptor or HER2 / neu, and cancer cells with stem-like characteristics. The compositions and methods of the instant invention may also be useful for managing metastatic breast cancer, and visualizing breast cancer cells in patient's body. The compositions and methods of the instant invention may also be useful for treating ovarian cancer and managing metastatic ovarian cancer. The compositions and methods of the instant invention may also be useful for treatment and manageme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/22A61K31/337A61K45/06
CPCA61K38/2257A61K45/06A61K31/337A61K2300/00A61P15/00A61P15/08A61P35/00A61P35/04A61P43/00A61K38/22
Inventor CHEN, WEN Y.
Owner ONCOLIX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap